InvestorsObserver
×
News Home

Is Lantern Pharma Inc (LTRN) a Good Buy in the Biotechnology Industry?

Friday, October 27, 2023 10:30 AM | InvestorsObserver Analysts

Mentioned in this article

Is Lantern Pharma Inc (LTRN) a Good Buy in the Biotechnology Industry?

Lantern Pharma Inc (LTRN) is near the middle in its industry group according to InvestorsObserver. LTRN gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Lantern Pharma Inc gets a 64 rank in the Biotechnology industry. Biotechnology is number 66 out of 148 industries.

Overall Score - 51
LTRN has an Overall Score of 51. Find out what this means to you and get the rest of the rankings on LTRN!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 51 would rank higher than 51 percent of all stocks.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Lantern Pharma Inc Stock Today?

Lantern Pharma Inc (LTRN) stock is trading at $2.80 as of 10:25 AM on Friday, Oct 27, a rise of $0.01, or 0.36% from the previous closing price of $2.79. The stock has traded between $2.80 and $2.84 so far today. Volume today is light. So far 1,143 shares have traded compared to average volume of 20,456 shares. Click Here to get the full Stock Report for Lantern Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App